The mechanism underlying the anabolic effect of estrogen on the skeleton is unclear. Results: We report that estrogen-induced bone formation in mice occurs through oxytocin (OT) produced by osteoblasts in bone marrow. Conclusion: Feed-forward OT release in the bone marrow by a rising estrogen level may facilitate rapid skeletal recovery after lactation. Significance: The study highlights a novel mechanism for estrogen action on bone.
phenotype of OTR deficiency to an osteoblastic, rather than an osteoclastic defect. Physiologically, feed-forward OT release in the bone marrow by a rising estrogen concentration may facilitate rapid skeletal recovery during the latter phases of lactation.
Oxytocin (OT) is a nanopeptide synthesized in the hypothalamus and released into circulation by the posterior pituitary. Its primary function is to mediate the milk ejection reflex in nursing mammals (1) . It also augments uterine contraction during parturition (2) . Serum OT levels peak during late pregnancy and are maintained during lactation.
These periods correspond, respectively, to maximal fetal and post-natal bone growth, which in turn leads to maternal losses from the skeleton of ~120g of calcium (3, 4) . Hormonal adaptations, including low estrogen and persistently elevated PTHrP levels, as well as increased sympathetic tone all lead to a state of maternal hyper-resorption and intergenerational calcium transfer (3) (4) (5) . However, the profound bone loss of lactation recovers fully within a relatively short period even as estrogen levels are slowly returning to normal (5) . The mechanism(s) responsible for this dramatic anabolic skeletal recovery remain poorly understood.
To determine whether OT mediates any or all of these functions during pregnancy and/or lactation, we studied whether OT directly affects the skeleton. While intracerebroventricular OT did not affect bone remodeling, peripheral administration did affect bone remodeling and bone mass (6) . However, instead of recapitulating the elevated resorption and bone loss that occurs during pregnancy and lactation, peripherally injected OT markedly increased bone mass in both wild type and ovariectomized mice (6, 7) . In line with its peripheral effect, we found that osteoblasts possess abundant OT receptors (OTRs) and that OT triggers osteoblast differentiation to a mature mineralizing phenotype (6) . Consistent with this anabolic action, the genetic deletion of OT or the OTR in mice decreased osteoblast differentiation and bone formation, resulting in osteopenia (6) .
Furthermore, the increased bone formation noted normally during pregnancy was attenuated in OT -/-mice, as was fetal skeletal mineralization in OT -/-pups (8) . Together, these findings suggest that the anabolic action of OT may, in fact, facilitate maternal skeletal recovery and fetal skeletogenesis.
OT is known to be produced in peripheral tissues, such as the testes, ovary, heart, lung, and vascular tissue (9) (10) (11) (12) (13) (14) . In certain of these organs, estrogen regulates OT and/or OTR expression (15, 16) . Likewise, we find that OT is produced in abundance by bone marrow osteoblasts in response to estrogen, with the potential of exerting an anabolic effect on the skeleton (17) . Estrogen at high doses is a skeletal anabolic (18) , but its precise mechanism remains unknown. Here, we show that the osteoblastic OTR is required for the full anabolic action of estrogen. We postulate that an autocrine feed-forward OT/OTR loop exists in which estrogen releases OT from osteoblasts, which then acts upon osteoblastic OTRs to further amplify estrogen action. This could be particularly advantageous for maternal skeletal replenishment during the post-partum period, when estrogen levels are returning to normal and OT is high (19) .
EXPERIMENTAL PROCEDURES
Mouse Models − OTR -/-mice, originally created on a C57BL/6Jx129Sv background 6 , have been back-crossed with C57BL/6J mice for >15 generations. OTR fl/fl mice were developed as described previously on a C57BL/6J background (33) Micro-CT was performed on trabecular bone (µCT40, Scanco). For histomorphometry, groups of female mice received either calcein (15 mg/kg, i.p.) 10 and 2 days prior to sacrifice, or for specific experiments, calcein and xylenol orange (90 mg/kg, i.p.) 6 and 1 days prior to sacrifice, respectively. Standard protocols were utilized for sectioning the spine and femur and for dynamic and static histomorphometry (24, 35) .
In separate experiments, female mice were injected either with a single dose or biweekly with 50 µg/kg of 17β-estradiol or 0.9% w/v NaCl (vehicle) i.p. (cumulative weekly dose 100 µg/kg). In certain instances, blood ( 1 ml) was collected by intracardiac puncture. Osteocalcin and OT were measured using a mouse-based Osteocalcin (DRG Inc., NY) and OT (Enzo Inc., PA) ELISA kits, respectively.
Cell Experiments − Osteoblasts were isolated from OTR -/-and wild type female mouse bone marrow-adherent fraction or from calvaria of 5 day-old pups (gender unknown). Cells were cultured in phenol-red-free α-MEM (Gibco) with 10% charcoal-stripped FCS in the presence of 50 µg/ml ascorbic acid and 10 mM β -glycerophosphate (Sigma) for mRNA and protein extraction, and Von Kossa staining.
MC3T3-E1 cells were kindly provided by Dr. Anna Teti (University of L'Aquila, Italy). These cells were transfected with OTR siRNA or vector-only duplexes (50 nM) using lipofectamine 2000 (Invitrogen). Western blotting and qPCR were performed as described (6) .
It is difficult to determine the sex of the mice before 2 to 3 weeks. However, we utilized 5 day-old pups to isolate calvarial osteoblasts for PCR and Western blotting, rather than bone marrow-derived osteoblasts because of the possible contamination of these cultures. Older mice cannot be used for calvarial osteoblast cultures due to difficulties in getting highly pure osteoblast fractions. We also show that estrogen induces robust OT and OTR expression in male osteoblasts (Supplementary Figure 1) ; the time course of the effect is concordant with that seen in female cells (17) .
RESULTS
Estrogen is known to exert its anabolic action in rodents by enhancing osteoblast differentiation, although an effect on apoptosis has also been described (20) . To study if OT mediates estrogen effects on osteoblastogenesis, we questioned whether OTR -/-calvarial osteoblasts were less sensitive to estrogen-induced differentiation. We found that 17β-estradiol increased mineralizing osteoblast colony (CFU-Ob) formation in wild type bone marrow stromal cell cultures, but not in cultures from OTR -/-mice ( Figure 1A ). Likewise, 17β-estradiol-induced expression of the differentiation gene osteocalcin in wild type osteoblasts, albeit modest, was abolished in OTR -/-cells ( Figure 1Ba ). These data show that the augmentation of osteoblast differentiation by estrogen requires OTRs.
To understand why estradiol failed to increase the differentiation of OTR -/-osteoblasts, we studied the expression of the critical transcription factors Runx2, Osterix, and ATF4 in cultures of calvarial osteoblasts isolated from 5 day-old male and female pups. Western blotting revealed that 17β-estradiol significantly increased Runx2 and ATF4 protein expression in wild type cells, whereas these increases were blunted in OTR -/-cells up to 12 hours ( Figure 1C) . qPCR confirmed the up-regulation of ATF4 mRNA (Figure 1Bb ). Likewise, 17β-estradiol modestly but significantly increased Osterix mRNA at both 6 and 12 hours in wild type osteoblasts, but not in OTR -/-cells ( Figure 1Bc ). We did not observe parallel changes in Osterix protein with estrogen. However, levels remained lower in OTR -/-cells for up to 12 hours after 17β-estradiol treatment ( Figure 1C ).
To confirm these ex vivo findings from primary bone marrow and calvarial osteoblast cultures, we used siRNA to knock down OTR expression in a pre-osteoblastic cell line, MC3T3.E1. Western blotting and qPCR showed a dramatic reduction in OTR protein and mRNA, respectively, in OTR-silenced cells ( Figure 2A ). Whereas 17β-estradiol significantly increased Runx2, Osterix, ATF4 and osteocalcin mRNA in vector-treated cells, this effect was profoundly attenuated in OTRsilenced cells ( Figure 2B ). The data suggest that the pro-osteoblastic actions of 17β-estradiol require OTR expression, and occur mainly through the up-regulation of Runx2 and ATF4, although other pathways may also be involved.
As is evident, all genes are not equally responsive to estrogen. Furthermore, estrogen responsiveness can vary depending on osteoblast source, differentiation state, and culture conditions. However, it is important to note that the results from bone marrow osteoblast cultures showed overall concordance with results from calvarial osteoblast cultures in terms of the lack of responsiveness of OTR -/-cells to 17β-estradiol.
Our previous data showing that 17β-estradiol induces OT and OTR expression in osteoblasts (17) prompted us to further determine whether the effects of estrogen on osteoblast OT expression were dependent on OTRs. We found that OT mRNA expression in response to 17β-estradiol was abrogated in OTR -/-(female) and OTR-silenced MC3T3.E1 osteoblasts ( Figure 2C ), suggesting that OTRs are required for estrogen-induced OT production. In line with this, OTR -/-mice failed to show an increase in serum OT levels in response to 17β-estradiol ( Figure 2D ). Knowing that OTRs are required for estrogeninduced OT expression, we further hypothesized that OT acts on its receptor to induce its own production. We found using qPCR that OT did induce OT mRNA in MC3T3.E1osteoblasts at 6 hours ( Figure 2E ). This putative autocrine stimulation was abolished by the OTR antagonist atosiban ( Figure 2E ), establishing that the OT-induced OT expression required OTR activation.
Data from this and our previous study (17) support a hypothesis whereby estrogen induces the expression of both OT and OTR. The induced OT then acts upon the OTR in an autocrine loop to amplify the anabolic effects on estrogen. To test this hypothesis in vivo, we treated two month-old female OTR -/-mice or wild type littermates with 17β-estradiol (50 µg/kg) or vehicle, biweekly, for 30 days (cumulative weekly dose of 100 µg/kg). This is consistent with the cumulative weekly dose of between 70 and 280 µg/week (10 to 40 µg/kg/day) used by others (21, 22) . Histomorphometry showed lower trabecular BV/TV, Tb.Th, MAR and BFR in placebotreated OTR -/-mice compared with placebotreated wild type littermates, confirming previous results (6) (Figure 3 (6), and did not significantly change in either group upon 17β-estradiol treatment (Table 1) . Concordant with a bone formation defect, while 17β-estradiol elevated serum osteocalcin, a bone formation marker in OTR -/-and wild type mice, the response was significantly (p < 0.01) attenuated in OTR -/-mice ( Figure 3D ). In sum, the overall failure of OTR -/-mice to display a full anabolic response to 17β-estradiol suggests that the bone-forming action of estrogen is, at least in large part, OTRdependent.
We next tested whether OT signalling also played a role in mediating the effect of estrogen on bone mass in hypogonadal mice. For this, mice were ovariectomized or sham operated and given either 17β-estradiol or vehicle, as above. Areal bone mineral density measurements 30 days after ovariectomy revealed significant decrements in wild type and OTR -/-mice at the lumbar spine and femur ( Figure 4A and 4B) .
However, when compared to zero-dose controls, both shamoperated and wild type mice treated with 17β-estradiol showed increases in BMD, whereas the respective OTR -/-mice did not ( Figure 4C  and 4D ). This suggested that, as in the eugonadal state, an intact OTR axis contributes to the action of estrogen in hypogonadism.
We sought to determine definitively whether the effect of 17β-estradiol in increasing bone mass was osteoblast-mediated or whether there was an osteoclastic component. For this, we generated osteoblastor osteoclast-specific OTR-deficient mice by crossing OTR fl/fl mice with Col2.3-Cre or TRAP-Cre mice, respectively (see 'Methods'). Figure 6D ). At the 3 week time point, there was a significant BMD difference between 17β-estradioltreated Col2.3-Cre + /OTR fl/fl and control mice ( Figure 6D ). That the anabolic effect of 17β-estradiol on bone mass was abolished in mice selectively lacking OTRs in osteoblasts, suggests that neither the osteoclast nor the nervous system contributes to the effect, at least, in large part.
DISCUSSION
We hypothesize that estrogen acts to enhance osteoblast differentiation and bone formation, at least, in part, by stimulating the production of OT, which then acts on its own receptor to trigger further OT release. This, we hypothesize, constitutes a local autocrine circuit that amplifies bone formation triggered by estrogen.
Our hypothesis is based upon several observations. First, there is evidence from others (7) and us (6) that OT enhances osteoblastogenesis, bone formation, and/or bone mass through a peripheral action on osteoblast OTRs. In this respect, OT mimics the estrogen, which, at higher-than-antiresorptive doses, stimulates osteoblastogenesis with some effects on osteoblast apoptosis (20) . Second, this study provides in vitro evidence that OT is downstream of estrogen. Thus, the deficiency of OTRs in OTR -/-osteoblasts or OTR-silenced cells markedly reduces the effect of 17β-estradiol on mineralized colony formation, as well as the expression of osteoblast certain differentiation genes and transcription factors. Third, we have shown that OT is produced by osteoblasts and that 17β-estradiol stimulates OT expression within 2 hours (17). 17β-estradiol also stimulates OTR expression, but with a slower time course (17) . Here, we show that estrogen action on OT production is dependent upon OTR expression; the absence of OTRs in OTR -/-osteoblasts or OTR down-regulation in silenced cells thus abolishes estrogen-induced OT expression. Finally, the effects of 17β-estradiol on bone mass and bone formation are abolished/attenuated in OTR -/-mice, and importantly, in osteoblast-specific Col2.3-Cre + /OTR fl/fl mice. In both models, no appreciable effects on osteoclast (resorption) parameters were noted. Several implications arise from these studies. First, is the recurring notion that not only do primitive pituitary hormones, such as TSH, FSH and ACTH, have receptors in extra-endocrine targets, such as bone (23) (24) (25) , but also that certain of these ligands, including TSHβ, ACTH and OT, themselves can be expressed in a host of tissues (17, 26, 27) . We suggest that estrogen stimulates an autocrine OT circuit in which locally produced OT activates its own receptor. This role appears consistent with the historic function of OT in mineral homeostasis observed in lower mammals (9, 28) .
Second, we have injected 17β-estradiol at a dose of 50 µg/kg, biweekly, which corresponds to a cumulative dose of 100 µg/kg per week. This is consistent with doses between 10 and 40 µg/kg/day (or cumulative weekly doses of 70 to 280 µg/kg) used by others to prevent bone loss due to aging or ovariectomy (21, 22) .
Ovariectomy is associated with increased resorption and formation, at least in the acute setting, and the effects of estrogen in restoring bone mass arise mainly from its anti-osteoclastic action (29) in a hyper-resorptive state. Here, we show that the effects of 17β-estradiol on bone mass in ovariectomized mice are also dependent on an intact OTR axis. However, in order to obviate confounding effects of elevated resorption and its inhibition by estrogen, and short of using chronically estrogen-deprived rodents (30), we have instead used wild type mice with normal bone resorption and bone formation. As has been noted by others (21) in non-ovariectomized settings, we find that 17β-estradiol does not affect osteoclast parameters, whether or not the mice are devoid of OTRs. In contrast, osteoblast numbers, bone formation, and cortical and trabecular bone mass were all enhanced significantly with 17β-estradiol in wild type mice. This anabolic action was attenuated in OTR -/-mice, suggesting that the effects of estrogen on bone mass were, at least in part, dependent on OTRs.
Third, our study definitively rules out mediation of OT effects on the skeleton through the osteoclast or the central nervous system. We have shown previously that intracerebroventricular OT does not affect certain acute bone formation parameters (6) Overall, our findings may have implications both biologically and clinically. The parallel actions of estrogen and OT on bone formation, and particularly a feedforward loop for estrogen-mediated OT release from the osteoblast, may be of significance. For example, OT levels are high late in pregnancy, during parturition, and postpartum (19) .
These time periods also correspond to a period of relentless pressure on the maternal skeleton for bio-available calcium, initially to support prenatal fetal mineralization, and subsequently, for postnatal nutrition from lactation (3, 4) . Not surprisingly, significant cortical and trabecular bone loss are a consequence of lactation, as well as suppressed estrogen concentrations (4). However, with the onset of menses, and immediately post-weaning, there is a rapid restoration of bone mass. This "anabolic" phase is likely to be multifactorial in origin, and has been attributed to return of prepregnancy estrogen levels, a change in PTHrP expression locally and/or systemically, and a reduction in osteocyte osteolysis (31) . However, skeletal recovery is relatively quick suggesting that estrogen restoration alone cannot be the sole explanation. Similarly, although skeletal PTHrP is up-regulated with weaning, it is not essential for bone mass recovery (4) . On the other hand, in the postpartum period during lactation, as estrogen production gradually returns, OT levels remain elevated, probably due to chronic suckling. A feed-forward autocrine network in the marrow niche, whereby rising estrogen levels enhance local OT production ultimately leading to greater bone formation through the OTR, appears to be a plausible additional mechanism that could explain the "anabolic" phase of skeletal recovery post-lactation.
Finally, the repletion of osteoblast OT signaling may represent a non-estrogenic means of restoring bone in those forms of bone loss that are characterized mainly by osteoblast dysfunction (32) . Indeed, human OT is in use for inducing labor, and it is not inconceivable that bone-specific OT analogs may spare the reproductive organs. Finally, and more broadly, future studies are needed to evaluate if the feed-forward OT loop, as well as short loops of other pituitary hormones, operate in tissues other than the skeleton and traditional endocrine targets. Areal bone mineral density (aBMD, Piximus) measurements at the spine and femur of sham-operated (Ctr) or ovariectomized (OVX) OTR -/-and wild type (OTR +/+ ) mice that were injected with 17β-estradiol (E 2 , 50 µg/kg) or placebo biweekly (cumulative dose 100 µg/kg/week). Panel A and B show the effect of ovariectomy against sham operation in the two genotypes, whereas panels C and D display the effect of E 2 against placebo within the various groups. Statistics: mean of percent (%) change shown using respective controls + SEM; n = 5-6/group; Students t-test with Bonferroni correction compares OVX versus control (A and B) and E 2 versus zero-dose (C and D); *p < 0.05; **p < 0.01. 
